Inherited cardiovascular diseases encompass a wide range of prevalent conditions, including cardiomyopathies (e.g., hypertrophic, dilated), cardiac channelopathies (arrhythmia syndromes), and aortopathies. These genetic disorders are major contributors to both sudden cardiac death (SCD) and the progressive onset of heart failure. SCD is often the first manifestation, typically caused by a life-threatening arrhythmia like ventricular fibrillation that halts effective blood circulation.
The clinical picture can be complex; a severe arrhythmia may be the earliest indicator of an underlying cardiomyopathy, even when structural heart changes are minimal, making it difficult to distinguish from a primary ion channel disease. Recognizing this genetic basis is crucial. Consequently, clinical guidelines for the management of heart failure now increasingly recommend genetic testing, particularly for non-ischaemic cardiomyopathies, to establish a precise diagnosis, guide targeted therapies, and identify at-risk family members who could benefit from early intervention.
For clinicians and their patients, this means moving from uncertainty to clarity.
CardioSeq provides crucial insights at every stage of patient care:
Clarity in Diagnosis
Pinpoint the genetic cause of complex conditions with extensive coverage for:
- Cardiomyopathies (73 genes)
- Arrhythmias (36 genes)
- Mitochondrial & Metabolic Disorders (60 genes)
- Congenital Heart Disease & more
Personalisation of Treatment
Leverage high-precision diagnostics and ACMG/AMP-guided interpretation to create tailored treatment strategies and proactive risk management plans.
Foresight for Families
Empower patients with clear, actionable information vital for genetic counselling, cascade screening, and future family health planning.
Enhance your approach to cardiac care with the definitive genetic insights from CardioSeq.
For further details please mail us at lab@karkinos.in
*Coverage for coding sequences only.